Members
The Stop TB Working Group on TB Drug Development coordinates worldwide TB R&D activities aimed at delivering an affordable and faster cure. The activities of the Working Group's members span the wide spectrum from basic research to discovery, clinical development, and registration. Each Working Group member pursues its own drug-development activities. Through the Working Group, these organizations collaborate on joint initiatives.
Members List (updated September 22, 2008)
Dr. Koen Andries, Tibotec
Dr. Venkataraman Balasubramanian, AstraZeneca R&D India
Dr. Tanjore Balganesh, AstraZeneca R&D India
Dr. William Bishai, Johns Hopkins School of Medicine
Prof. Jonathan Blackburn, University of Cape Town
Ms. Florence Bordon-Pallier, sanofi-aventis
Dr. Allen Casey, Infectious Disease Research Institute
Prof. Gail Cassell, Eli Lilly and Company
Dr. Kenneth Castro, U.S. Centers for Disease Control and Prevention
Dr. Richard Chaisson, Johns Hopkins University Center for TB Research
Dr. Michael Cynamon, VAMC, SUNY, Upstate Medical University
Dr. Noroi Doi, Japan Anti-Tuberculosis Association; Research Institute of Tuberculosis
Dr. Carol Dukes Hamilton, Infectious Diseases Society of America (representative); Duke University Medical Center
Dr. Ken Duncan, Bill & Melinda Gates Foundation
Dr. Leo Einck, Sequella, Inc.
Dr. Bernard Fourie, Medicine in Need (Mend)
Dr. Scott Franzblau, Institute for Tuberculosis Research, University of Illinois at Chicago
Dr. Jennifer Fujii, Vertex Pharmaceuticals
Dr. Barrington Furr, AstraZeneca
Dr. Lawrence Geiter, Otsuka Pharmaceutical Company
Dr. Jan Gheuens, Bill & Melinda Gates Foundation
Dr. Ann Ginsberg, TB Alliance
Dr. Federico Gómez de las Heras, GlaxoSmithKline
Dr. Jacques Grosset, Johns Hopkins University School of Medicine
Dr. Trudy Grossman, Vertex Pharmaceuticals
Dr. Malgosia Grzemska, World Health Organization
Mr. Mark Harrington, Treatment Action Group
Dr. Gary Horwith, Sequella, Inc.
Ms. Heather Ignatius, TB Alliance
Dr. Amina Jindani, St. George's, University of London
Dr. Rajender Kamboj, Lupin Limited
Dr. Edward Kesicki, Infectious Disease Research Institute
Dr. Barbara Laughon, National Institute of Allergy and Infectious Diseases, NIH, DHHS
Dr. Didier Leboulleux, sanofi-aventis
Dr. Ann Lenaerts, Colorado State University
Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Diseases (The Union)
Dr. Christopher Locher, Vertex Pharmaceuticals
Dr. Zhenkun Ma, TB Alliance
Prof. Stephen Matlin, Global Forum for Health Research
Dr. David McNeeley, Tibotec
Prof. Dennis Mitchison, St. Georges, University of London
Dr. Carole Mitnick, Harvard Medical School
Dr. Peter Mueller, Vertex Pharmaceuticals
Dr. Ute Muh, Vertex Pharmaceuticals
Dr. Carol Nacy, Sequella, Inc.
Dr. P. R. Narayanan, Tuberculosis Research Centre, Chennai (retired)
Dr. Rick O'Brien, Foundation for Innovative New Diagnostics
Mr. Matti Ojanen, AstraZeneca PLC
Dr. Philip Onyebujoh, WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Dr. Ian Orme, Colorado State University
Dr. Shreemanta Parida, Max Planck institute for Infection Biology
Dr. Jerome Premmereur, TB Alliance
Dr. John Rex, AstraZeneca R&D
Prof. Robert Ridley, WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Dr. Doris Rouse, RTI International
Dr. Boitumelo Semete, Council of Scientific Industrial Research (CSIR) in South Africa
Dr. Tado Shimao, Japan Anti-Tuberculosis Association; Research Institute of Tuberculosis
Dr. Christine Sizemore, National Institute of Allergy & Infectious Diseases (NIH)
Prof. Peter Small, Bill & Melinda Gates Foundation
Dr. Melvin Spigelman, TB Alliance
Dr. Martin Springsklee, Bayer Healthcare
Dr. Charles K. Stover, Pfizer Inc
Dr. Hulda Swai, Council of Scientific Industrial Research (CSIR) in South Africa
Mr. Javid Syed, Treatment Action Group
Dr. John Thomson, Vertex Pharmaceuticals
Dr. Tamari Trapaidze, Welfare Foundation
Dr. Cynthia Tuthill, SciClone Pharmaceuticals, Inc
Dr. Anna Upton, TB Alliance
Mr. Wim Vandevelde, European AIDS Treatment Group (EATG)
Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention
Mr. Todd Waldman, Easton Associates
Prof. Gerhard Walzl, Stellenbosch University
Dr. Tiansheng Wang, Vertex Pharmaceuticals
Dr. William Wells, TB Alliance
Dr. Abubakar Yaro, Africa Health Research Organization
|
